Cargando…
Ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in dogs
BACKGROUND: For the treatment of diabetes mellitus (DM) in dogs, novel insulins with decreased injection frequency while maintaining safety and efficacy are desirable. Insulin fused with immunoglobulin‐fragment‐crystallizable (Fc) has an ultra‐long plasma half‐life because it recycles through cells,...
Autores principales: | Hulsebosch, Sean E., Pires, Jully, Bannasch, Michael J., Lancaster, Thomas, Delpero, Andrea, Ragupathy, Ramya, Murikipudi, Sylaja, Zion, Todd, Gilor, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308417/ https://www.ncbi.nlm.nih.gov/pubmed/35621084 http://dx.doi.org/10.1111/jvim.16449 |
Ejemplares similares
-
An ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in cats
por: Gilor, Chen, et al.
Publicado: (2021) -
Evaluation of a machine learning tool to screen for hypoadrenocorticism in dogs presenting to a teaching hospital
por: Reagan, Krystle L., et al.
Publicado: (2022) -
Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
por: Miller, Michelle, et al.
Publicado: (2021) -
Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs
por: Munro, Matthew J. L., et al.
Publicado: (2021) -
Serum trypsin‐like immunoreactivity in dogs with diabetes mellitus
por: Hamilton, Kristen, et al.
Publicado: (2021)